I'm a relative newcomer, especially compared to long timers

New Post Public Reply Private Reply Replies (1) Message Board
DJknows DJknows #31949
569
I'm a relative newcomer, especially compared to long timers here, but even in my short time invested in CytoDyn , I can tell from a vast experience now in the gutter of OTC, what a real and true CEO is compared to the rampant cons and swindlers out there.

Just recently I posted:

Quote:
"Mind blowing" says Dr. Yo of Leronlimab results to be published.... he had said Dr. Patterson deserves the Nobel prize!

What's also mind blowing is how compassionate, generous and extraordinary CytoDyn's CEO, Dr. Nader Pourhassan is... he has such integrity, heart and unbelievale uniqueness in the OTC world and soon I believe the entire world will see that as well.

Dr. Patterson recently said:

Quote:
"CytoDyn is a company with huge heart and focus on patients"


Read More: https://investorshangout.com/post/view?id=575...z6LUo0jt00

I also posted some time in mid-April that I thought I heard Dr. Pourhassan encourage some to take advantage of having held long enough to see some profit... got some push-back from some here and even my first ever thumbs down (don't know from who since I cannot access my old email anymore where these notices are sent from IHang)... doesn't matter to me but in any case, those holding warrants can help the company and themselves... all good as I understand a small start-up needs infusions for immediate necessary transactions at times (like what CytoDyn must be going through at this time)... gotta spend money to make money as they say...

Having said this, I've gone back to listen to videos of interviews with Dr. Pourhassan and believe some have either been edited or even removed as I distinctly heard what I heard and have had no reason nor would I know how to make up such information. Anyway, in my search of interviews, numerous times now I've heard Dr. Pourhassan say government funding... I suspect that's what we'll be hearing about as soon as 'human data' is submitted to the FDA and/or published in medical journals, etc. PROOF is what everyone wants before they place their dollars behind Leronlimab (Vyrologix) !

And according to Dr. Pourhassan and Dr. Patterson, human data should be in place to the powers-that-be whether FDA, leading medical professionals, journals within four-to-six week from mid-April (that's what they were sayng then)... making that any time now...

Maybe it's too bad that gov't monies are contingent on that 'human data' PROOF and since that's not yet out... CytoDyn still has had to secure production and manufacturing of vials of Leronlimab ... so they and we find ourselves to be in this disposition....





















CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 17

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 85

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 57

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
ROBOTERA Puts Humanoid Robots Into Logistics Night Work

Updated Category News Views 76

Midnight warehouse work is where a humanoid robot has to quit posing and earn its keep. ROBOTERA arrived at the 2026 APEC CEO Summit with a useful answer to the usual shiny-robot nonsense: it says its machines are already working in logistics centers, handling parcel induction and taking on repetitive, physically demanding shifts that people understandably do not line up...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 104

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 41

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Gildan Lawsuit Puts Revenue Quality Under a Harsh Lens

Updated Category News Views 16

Inventory can hide a multitude of sins until somebody counts the boxes, and that is the ugly question hanging over Gildan Activewear. A federal securities class action alleges the company inflated reported sales and organic-growth figures by pushing excess product into wholesaler and distributor channels. Those are allegations, not findings of fact, and investors ought to...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 70

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 9

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 111

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading

Top 5 Most Recently Viewed Articles

BMO Continues to Support United Natural Foods with Price Target

Updated Category News Views 79

BMO Capital Markets Maintains Support for United Natural Foods BMO Capital Markets has reaffirmed its position regarding United Natural Foods (NYSE: UNFI), assigning a Market Perform rating with a price target set at $23.00. This decision came after productive discussions held with UNFI's senior executives, including CEO Sandy Douglas and CFO Matteo Tarditi, focusing on...

Continue Reading
HONOR's Ambitious Shift to AI Device Ecosystem Strategy

Updated Category News Views 202

HONOR's Bold New Strategy for AI Device Ecosystem In an ambitious move, global technology brand HONOR has laid out a comprehensive strategy to transform from a traditional smartphone manufacturer into a leader in the AI device ecosystem. This announcement marks a significant pivot towards embracing advanced technologies designed to maximize human potential. The new...

Continue Reading
Roche's Strategic Move: Acquiring 89bio for Innovative Therapies

Updated Category News Views 254

Roche's Strategic Acquisition of 89bio Roche's recent decision to acquire 89bio, a clinical-stage biopharmaceutical company, highlights its commitment to enhancing treatment options for patients suffering from metabolic diseases. This acquisition centers around 89bio’s innovative therapy, pegozafermin, which is showing promise for treating moderate to severe Metabolic...

Continue Reading
Baby Safety Alliance Elevates Parent Confidence in Products

Updated Category News Views 137

Baby Safety Alliance Strengthens Trust for Parents The Baby Safety Alliance is excited to announce a significant expansion of its Verification Program. This vital initiative, previously recognized as the JPMA Certification Program, aims to simplify the process for parents seeking safe and reliable products for their babies and children. Growth of the Verification Program...

Continue Reading
Ken Kendrick: A Journey of Resilience and Recognition

Updated Category News Views 646

Ken Kendrick’s Recognition by the Horatio Alger Association Ken Kendrick, the managing general partner of the Arizona Diamondbacks, has recently been honored by the Horatio Alger Association, which has selected him for its Member Class of 2025. This prestigious recognition is awarded to individuals who have overcome personal and professional adversities, showcasing...

Continue Reading